Sab Biotherapeutics Inc (SABS)

$SABS SABS avoided the high beta, Friday bloodbath. Apparently, being unknown is a blessing in disguise.

$SABS Current Stock Price: $4.42 Contracts to trade: $4.0 SABS Feb 20 2026 Call Entry: $1.40 Exit: $2.23 ROI: 60% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$SABS $NVDA $PLTR Chart people, look at $SABS the last few months and tell me if I'm crazy for thinking this thing is ready for a major breakout?

$SABS Perceptive Advisors Biotech Investor Joseph Edelman holds 3.47 million shares. https://youtu.be/M0RjFqj9ExU?si=QwYXgtYTrSFlCeAG

$SABS giddyup

$SABS solid volume lately, I remember the 15k-20k days

$SABS Chart is looking nice for the last three months. Steady rise!

$AGRI It amazes me that this gets more attention than something like $SABS

$SABS they can keep paying me for borrowing my shares this is a life changing therapy for young people who develop type one diabetes and big money is behind them

$SABS live short interest 7.98%, CTB 31.74, outside of Chardan Capital being here i see a lot of green lights. OS: 47.61M Float: 37.02M Market Cap: $201.4M Key Dilution Weapons Active • 150M Series B Pref warrants @ $1.75 (institutional) • 63.9M remaining Series B Pref convert @ $1.75 • 6.7M remaining Series A-2 Pref convert @ $6.30 • $75M UBS ATM (unused, unrestricted) • $300M shelf (unused) This is an institutional biotech cap table built around large structured private preferred financings rather than retail pipes. RA/Commodore/Blackstone/Vivo/RTW/Sessa et al are not “toxic note” shops, they are long-horizon biotech allocators using pref + warrant structures for asymmetric upside. The cap table math is heavy (150M warrants + >70M potential converts), but it is aligned with clinical funding rather than death-spirals. The ATM and shelf simply provide optionality for future program scaling. Cash runway (~4 years) removes near-term financing pressure. Completed Dilutive Events (last 3 years) July 2025 – Private Placement (Series B Convertible Preferred + Warrants) • 100,000,000 shares equivalent @ $1.75 • 150,000,000 warrants @ $1.75 • $175,000,000 raised Banks: Leerink, UBS, Chardan, Oppenheimer Investors: RA Capital, Commodore, Vivo, Blackstone, Spurce Street, Forge Life, Woodline, Sessa, T1D, ATW Date: 2025-07-21 07:30 October 2023 – Private Placement (Series A Convertible Preferred + Warrants) • 11,904,762 shares equivalent @ $0.63 • 206,349,206 warrants • $7,500,000 raised Bank: Chardan Investors: BVF, Commodore, JDRF T1D, Marshall Wace, RA Capital, RTW, Sessa Date: 2023-10-02 07:30 December 2022 – Private Placement • 7,300,000 shares @ $1.08 • 7,300,000 warrants • $7,900,000 raised Bank: Brookline Investors: Denny Sanford, Dominion, Firstfire, Iroquois, Mank, Warberg (and others) Date: 2022-12-07 17:16 Deal Memory (Price Levels That Matter) $1.75 (2025 institutional pref/follow-on anchor) $0.63 (2023 Series A financing) $1.08 (2022 PP) Current spot ~$4.00–$4.25 Structurally heavy but not toxic. Dilution optionality sits with institutional biotech funds holding deep pref + warrant packages, not floating VWAP convertibles. The capital stack funds multi-year R&D without retail bleed, and the shelf/ATM combo is idle rather than actively drawn. This is what well-capitalized clinical platforms look like pre-late-stage readouts.